Progyny, Inc.

What they do

Progyny provides fertility benefits through its Smart Cycle treatment bundles, which include diagnostic testing, IVF, and preimplantation genetic testing, along with care management services. It also offers Progyny Rx, an integrated pharmacy benefits solution for fertility medications, available only with the fertility benefits solution. The company generates revenue from utilization-based case rates and per-employee-per-month (PEPM) fees, with PEPM fees representing 1% of total revenue in 2025 and 2024.

Revenue drivers

• Fertility Benefits Solution — Billed via bundled case rates for Smart Cycles, varying by service type and clinic location; revenue grew 7.6% to $230.2 million in Q2 2026.
• Progyny Rx (Pharmacy Benefits Solution) — Billed on medication dispensed; revenue grew 1.2% to $120.3 million in Q2 2026.
• Population-Based PEPM Fees — Per-employee-per-month fees, representing 1% of total revenue, providing access to PCAs and digital tools regardless of treatment.

Recent performance

In Q2 2026, revenue increased 5.3% year-over-year to $350.5 million, with gross margin expanding to 25.5%. Net income rose to $28.1 million, or $0.34 per diluted share, from $17.1 million in Q2 2025. Adjusted EBITDA was $62.1 million, up from $57.9 million. Excluding the impact of a previously disclosed large client that did not renew for 2025, revenue grew 11.0%.

Strategy

Management emphasizes expanding its platform across the continuum of women's health, including pregnancy, menopause, and parent/child wellbeing. The company continues to invest in its data-driven platform and care management services to drive clinical outcomes and cost efficiency. It is also returning value to shareholders, having repurchased over 2 million shares under the current authorization.

Risks

• Regulatory patchwork — State and federal laws on reproductive rights could create a patchwork that limits uniform benefit offerings and increases compliance costs.
• Licensing requirements — Failure to maintain state TPA, PBM, or utilization review licenses could result in penalties, suspension, or loss of license, impacting operations.
• HIPAA compliance — As a Business Associate, any breach of protected health information could lead to investigation, penalties, and contractual breaches.
• Client concentration and retention — The loss of a large client, such as the one that did not renew for 2025, can materially impact revenue and growth.

Outlook

Management notes favorable selling season momentum, with new lives and early commitments pacing ahead of last year. They have removed most client retention risk with largest accounts. Continued investment in platform and shareholder returns is expected.